Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review

作者: Andres Martin Acosta , ShriHari S. Kadkol

DOI: 10.5858/ARPA.2015-0475-RS

关键词: Signal transductionViral OncogeneMelanomaNeuroblastoma RAS viral oncogene homologCutaneous melanomaCancer researchMitogen-activated protein kinaseMAPK/ERK pathwayProtein kinase ABiology

摘要: The mitogen-activated protein kinase (MAPK) signaling pathway is a cascade of kinases that act in sequential and predominantly linear fashion, albeit displaying some cross talk with other cascades. Mutations proteins integral to the MAPK are present more than 50% cutaneous melanomas. most frequently mutated v-raf murine sarcoma viral oncogene homolog B (BRAF), followed by neuroblastoma Ras (NRAS). Recently, development targeted drugs for treatment BRAF-mutant melanoma has led widespread implementation molecular assays detection specific BRAF mutations. There have been attempts standardize testing mutations, but this not achieved so far. Here we provide an updated review on role pathogenesis melanoma, focusing several different mutations their diagnostic therapeutic implications.

参考文章(33)
Letizia Porcelli, Gabriella Guida, Stefania Tommasi, Michele Guida, Amalia Azzariti, Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib? Cancer Chemotherapy and Pharmacology. ,vol. 76, pp. 433- 438 ,(2015) , 10.1007/S00280-015-2796-6
Matteo S Carlino, Georgina V Long, Richard F Kefford, Helen Rizos, None, Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma Critical Reviews in Oncology Hematology. ,vol. 96, pp. 385- 398 ,(2015) , 10.1016/J.CRITREVONC.2015.08.021
Kevin Qu, Qiulu Pan, Xi Zhang, Luis Rodriguez, Ke Zhang, Hairong Li, Albert Ho, Heather Sanders, Anthony Sferruzza, Shih-Min Cheng, Diedre Nguyen, Dan Jones, Frederic Waldman, Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. The Journal of Molecular Diagnostics. ,vol. 15, pp. 790- 795 ,(2013) , 10.1016/J.JMOLDX.2013.07.003
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion-Sileni, Kamil Drucis, Ivana Krajsova, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V Long, Keith Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D Rubin, Shonda M Little, Dirk Schadendorf, None, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib The New England Journal of Medicine. ,vol. 372, pp. 30- 39 ,(2015) , 10.1056/NEJMOA1412690
Allie H. Grossmann, Kenneth F. Grossmann, Michelle L. Wallander, Molecular testing in malignant melanoma. Diagnostic Cytopathology. ,vol. 40, pp. 503- 510 ,(2012) , 10.1002/DC.22810
Megan Lyle, Georgina V. Long, Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma Journal of Clinical Oncology. ,vol. 31, pp. 3176- 3181 ,(2013) , 10.1200/JCO.2013.50.4662
Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop, Peter Hirth, Vemurafenib: the first drug approved for BRAF -mutant cancer Nature Reviews Drug Discovery. ,vol. 11, pp. 873- 886 ,(2012) , 10.1038/NRD3847
Harkanwal Halait, Kelli DeMartin, Sweta Shah, Stephen Soviero, Rachel Langland, Suzanne Cheng, Grantland Hillman, Lin Wu, H. Jeffrey Lawrence, Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma Diagnostic Molecular Pathology. ,vol. 21, pp. 1- 8 ,(2012) , 10.1097/PDM.0B013E31823B216F
Philippe Bahadoran, Maryline Allegra, Florence Le Duff, Elodie Long-Mira, Paul Hofman, Damien Giacchero, Thierry Passeron, Jean-Philippe Lacour, Robert Ballotti, Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2012.46.1061
Sally Cowley, Hugh Paterson, Pauline Kemp, Christopher J Marshall, Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells Cell. ,vol. 77, pp. 841- 852 ,(1994) , 10.1016/0092-8674(94)90133-3